Clinical Trial Update: Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cabazitaxel plus prednisone with octreotide for castration-resistant prostate cancer previously treated with docetaxel has been termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• PREDNISONE (Prednisone)
• Sandostatin (Octreotide acetate)

Snippet

Sponsor: University of Southern California | Conditions: Diarrhea, Hormone-resistant Prostate Cancer | Phase 2 | Status: TERMINATED